Clinical Efficacy of Anlotinib as Second-line Treatment on Patients with Extensive Small Cell Lung Cancer

Objective To observe and analyze the clinical efficacy and adverse reaction of anlotinib as the second-line treatment on extensive small cell lung cancer.

Methods We retrospectively analyzed the clinical data of the 30 patients with extensive small cell lung cancer. After the failure of the first-line chemotherapy, these patients rejected the second-line chemotherapy and voluntarily opted for oral targeted antitumor therapy with anlotinib. We evaluated the efficacy every two cycles and observed the adverse reaction.

Results Among 30 patients, there was 0 case with CR, 5 cases with PR, 17 cases with SD and 8 cases with PD. ORR was 16.7%, DCR was 73.3%, PFS was 4.2 months and OS was 8.6 months. The most common adverse reaction was fatigue, hypertension, anorexia, weight loss, etc. The incidence of grade 3/4 adverse reaction was 16.7%.

Conclusion Anlotinib as a second-line treatment for extensive small cell lung cancer has good curative effect and relatively low toxic side effects.